Market Trends of Global Cephalosporin Drugs Industry
This section covers the major market trends shaping the Cephalosporin Drugs Market according to our research experts:
The Fifth-generation Segment is Expected to Witness Healthy Growth Over the Forecast Period
The fifth-generation cephalosporins are found to be developed in the lab to specifically target resistant strains of bacteria. The fifth-generation cephalosporins include ceftobiprole, ceftaroline, and ceftolozane. These agents are sometimes referred to as the advanced generation, rather than the fifth-generation cephalosporins. Cephalosporins exhibit side effects similar to penicillin, along with drug allergy and hypersensitivity. Cephalosporins in general have been associated with little hepatotoxicity and rare instances of drug-induced liver injury. The ceftobiprole is found to be effective against methicillin-resistant Staphylococcus aureus (MRSA). The burden of infectious diseases across the world is increasing, which is resulting in the rising focus on diagnosis and treatment of the same.
Ceftobiprole has antipseudomonal characteristics that appear to be less susceptible to the development of resistance. Ceftaroline has also been described as the fifth-generation cephalosporin but does not have the antipseudomonal or VRE coverage of ceftobiprole. According to the study titled "Characterization and Clonal Diffusion of Ceftaroline Non-Susceptible MRSA in two Hospitals in Central Italy" published in the MDPI Antibiotics in August 2021, a novel cephalosporin with a low prevalence of resistance, ceftaroline is very effective against MRSA. Penicillin-binding protein (PBP) mutations and hospital clones of MRSA, such as CC5, CC8, or CC22, were among the resistance mechanisms. The fact that fifth-generation cephalosporins are effective against MRSA infections contracted in hospitals and that the number of infectious diseases is rising sharply as well as longer hospital stays is supporting the market's expansion.
According to the article 'The new fifth generation cephalosporins-a balance between safety and efficacy,' published in December 2020, ceftaroline fosamile, the combination ceftolozane/tazobactame, and ceftobiprole medocaril are the first representatives of the fifth-generation of cephalosporins used in therapy. These new antibiotics are valuable anti-infective agents with a positive balance between benefits and side effects. Thus, the studied segment is expected to drive the growth of the cephalosporins market in the forecast period.
The market is found growing as it has opened gates for an alternative for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Furthermore, ceftolozane is also combined with the β-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections generally exhibit resistance to all β-lactam antibiotics, unless this enzyme is inhibited. Hence, the rising use of combination therapies may drive the market during the forecast period.
Thus, owing to above-mentioned factors it is expected to drive segment growth over the forecast period.
North America is Expected to be the Largest Growing Segment in the Global Market
North America is expected to witness high growth due to the rising prevalence of infectious diseases, increasing healthcare expenditure, and a large population base. Furthermore, cefuroxime is a second-generation cephalosporin antibiotic that has a broad-spectrum activity and is commonly used for the treatment of both upper and lower respiratory tract infections, Lyme disease, and genitourinary tract infections. It is readily available and affordable, and it exists in both oral and parenteral forms. According to the Center for Disease Control and Prevention (CDC), during the year 2020, the number of new tuberculosis cases found in the United States was around 7,174, a rate of 2.2 per 100,000 persons, which are significantly high. Thus, the growing burden of infectious diseases is anticipated to boost market growth.
The market for cephalosporin medications is anticipated to rise over the projected period as a result of an increase in funding for research and development (R&D) of cephalosporin pharmaceuticals and antibiotics. For instance, in May 2022, CARB-X received up to USD 300 million over ten years from the Biomedical Advanced Research and Development Authority (BARDA), a division of the United States Department of Health and Human Services. Up to USD 70 million will be provided over three years by Wellcome, a global charity organization that promotes biomedical research to fight antibiotic resistance. Both contributed USD 355 million in the project's first six years as original backers. Therefore, such efforts by various organizations to develop antibiotics promote the market's expansion over the forecast period.
Furthermore, strategic activities adopted by the market players such as product launches, mergers, and acquisitions are expected to expand the market. For instance, in October 2021, Sandoz acquired GSK's cephalosporin antibiotics business. Through this acquisition, the company has acquired rights to three established brands (Zinnat, Zinacef, and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.
Also, there is an increase in consumption of cephalosporin, easier availability, a rise in demand for over-the-counter drugs, and an increase in bacterial infection in the region that helps in driving the market growth.
